These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
205 related articles for article (PubMed ID: 18572482)
1. [New biological drugs for the treatment of chronic inflammatory diseases]. Skov L; Hegedüs L; Madsbad S; Bendtzen K Ugeskr Laeger; 2008 Jun; 170(24):2162. PubMed ID: 18572482 [No Abstract] [Full Text] [Related]
2. [Biological response modifiers in the treatment of immunoinflammatory diseases]. Skov L; Bendtzen K Ugeskr Laeger; 2008 Jun; 170(24):2120-6. PubMed ID: 18565292 [TBL] [Abstract][Full Text] [Related]
3. [Biological drugs in the treatment of immunoinflammatory diseases]. Nielsen OH; Bendtzen K Ugeskr Laeger; 2008 Jun; 170(24):2103. PubMed ID: 18565288 [No Abstract] [Full Text] [Related]
4. Neutralization of macrophage migration inhibitory factor-novel approach for the treatment of immunoinflammatory disorders. Cvetkovic I; Stosic-Grujicic S Int Immunopharmacol; 2006 Oct; 6(10):1527-34. PubMed ID: 16919824 [TBL] [Abstract][Full Text] [Related]
5. Spurs in the hunt for new immunomodulatory drug targets. Ward SG; O'Neill LA Curr Opin Pharmacol; 2012 Aug; 12(4):439-43. PubMed ID: 22770734 [No Abstract] [Full Text] [Related]
6. XToll, a recombinant chaperonin 10 as an anti-inflammatory immunomodulator. van Eden W Curr Opin Investig Drugs; 2008 May; 9(5):523-33. PubMed ID: 18465663 [TBL] [Abstract][Full Text] [Related]
7. Emerging approaches for the therapy of autoimmune and chronic inflammatory disease. Cope AP; Feldmann M Curr Opin Immunol; 2004 Dec; 16(6):780-6. PubMed ID: 15511673 [TBL] [Abstract][Full Text] [Related]
8. Expanding possibilities in the treatment of patient groups with previously difficult-to-treat patients. Dörner T; Burmester GR Curr Opin Rheumatol; 2010 May; 22(3):235-6. PubMed ID: 20351494 [No Abstract] [Full Text] [Related]
9. [Biological dermatologic agents. The Danish Society of Dermatology]. Iversen L; Kragballe K; Ugeskr Laeger; 2007 Mar; 169(12):1100. PubMed ID: 17394811 [No Abstract] [Full Text] [Related]
14. B cell-targeted therapy with rituximab and autoimmune neuromuscular disorders. Stübgen JP J Neuroimmunol; 2008 Nov; 204(1-2):1-12. PubMed ID: 18783837 [TBL] [Abstract][Full Text] [Related]
15. [Is it possible to use immune checkpoint inhibitors in patients with autoimmune or inflammatory disease?]. Danlos FX; Lambotte O Med Sci (Paris); 2018; 34(6-7):516-518. PubMed ID: 30067199 [No Abstract] [Full Text] [Related]
16. B cell depletion: on the rise. Hinze CH; Grom AA J Pediatr; 2007 Apr; 150(4):335-7. PubMed ID: 17382106 [No Abstract] [Full Text] [Related]